These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20203166)

  • 1. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.
    Singh AK
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):553-6. PubMed ID: 20203166
    [No Abstract]   [Full Text] [Related]  

  • 2. Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting.
    Winkelmayer WC
    J Am Soc Nephrol; 2011 Jan; 22(1):1-2. PubMed ID: 21164031
    [No Abstract]   [Full Text] [Related]  

  • 3. Individualizing decision-making--resurrecting the doctor-patient relationship in the anemia debate.
    Agarwal R
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1340-6. PubMed ID: 20448071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment.
    Kliger AS; Fishbane S; Finkelstein FO
    Clin J Am Soc Nephrol; 2012 Feb; 7(2):354-7. PubMed ID: 22266571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does TREAT give the boot to ESAs in the treatment of CKD anemia?
    Singh AK
    J Am Soc Nephrol; 2010 Jan; 21(1):2-6. PubMed ID: 20035034
    [No Abstract]   [Full Text] [Related]  

  • 6. The new FDA labeling for ESA--implications for patients and providers.
    Manns BJ; Tonelli M
    Clin J Am Soc Nephrol; 2012 Feb; 7(2):348-53. PubMed ID: 22266575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triumph and tragedy: anemia management in chronic kidney disease.
    Novak JE; Szczech LA
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial perspective. Should hemoglobin targets for anemic patients with chronic kidney disease be changed?
    Parfrey PS
    Am J Nephrol; 2010; 31(6):565-6. PubMed ID: 20501992
    [No Abstract]   [Full Text] [Related]  

  • 9. The CARI guidelines. Biochemical and haematological targets. Haemoglobin.
    McMahon L;
    Nephrology (Carlton); 2008 Jul; 13 Suppl 2():S44-56. PubMed ID: 18713123
    [No Abstract]   [Full Text] [Related]  

  • 10. Erythropoiesis-stimulating agents in cancer.
    Arcasoy MO
    J Clin Oncol; 2008 Jun; 26(18):3097-8; author reply 3098-100. PubMed ID: 18565902
    [No Abstract]   [Full Text] [Related]  

  • 11. It's time to compare anemia management strategies in hemodialysis.
    Coyne DW
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp Therapy study for anemia management in dialysis patients?
    Berns JS
    Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):567-72. PubMed ID: 20601876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applying evidence into routine clinical care at a unit level: the exemplar of renal anaemia management.
    Gallagher MP; Cass A; Craig JC
    Nephrology (Carlton); 2010 Jun; 15(4):429-33. PubMed ID: 20609094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anemia: guidelines comparison].
    Del Vecchio L
    G Ital Nefrol; 2009; 26(6):686-94. PubMed ID: 19918751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Regarding the optimal hemoglobin target range in renal anemia].
    Maurin N
    Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Message to the FDA on ESAs: REMS is not enough, more studies are needed.
    Singh AK
    Clin J Am Soc Nephrol; 2010 Aug; 5(8):1355-8. PubMed ID: 20688885
    [No Abstract]   [Full Text] [Related]  

  • 17. The treatment of anemia in chronic kidney disease: understandings in 2006.
    Levin A
    Curr Opin Nephrol Hypertens; 2007 May; 16(3):267-71. PubMed ID: 17420672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Should we modify hemoglobin targets in CKD patients? FDA and EMEA statements].
    Martín de Francisco AL; Aljama P; Arias M; Górriz JL; Martínez Castelao A; Portolés J
    Nefrologia; 2007; 27(4):399-404. PubMed ID: 17944575
    [No Abstract]   [Full Text] [Related]  

  • 19. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
    Singh AK
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Debate: PRO Position. Should hemoglobin targets for anemic patients with chronic kidney disease be changed?
    Singh AK
    Am J Nephrol; 2010; 31(6):552-6; discussion 563-4. PubMed ID: 20501988
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.